{"id":29759,"date":"2022-05-25T15:00:57","date_gmt":"2022-05-25T13:00:57","guid":{"rendered":"https:\/\/www.cmtc.nl\/?p=29759"},"modified":"2025-02-25T15:56:27","modified_gmt":"2025-02-25T14:56:27","slug":"launch-global-dermatology-coalition","status":"publish","type":"post","link":"https:\/\/www.cmtc.nl\/en\/blog\/2022\/05\/25\/launch-global-dermatology-coalition\/","title":{"rendered":"Launch Global Dermatology Coalition"},"content":{"rendered":"

On May 25th 2022 a patient-led multi-stakeholder group of like-minded organizations \u2013 including dermatology patient organizations, health care professionals (dermatologists and dermatology nurses), researchers, and industry \u2013 announced the formation of the Global Dermatology Coalition. This announcement comes during the 75th World Health Assembly in Geneva, as a first step in changing perceptions about the often-severe impacts of these diseases and elevating their prioritization in health policy both at global and country levels.<\/p>\n

We as organisation are part of this Coalition.<\/p>\n

Skin, the largest and most visible organ of the body, plays a key role in protecting other organs from the outside world, while at the same time, is vulnerable to attack. This vulnerability can lead to highly burdensome and sometimes lethal dermatological conditions.\u00a0 Diseases of the skin, mucosae, nails and\/or hair are a leading cause of global disease burden (GDB).1 \u00a0They affect nearly 900 million people in the world at any time and are the fourth most frequent cause of human illness globally.1\u00a0\u00a0 Dermatologists diagnose and treat more than 3,000 different diseases, including atopic eczema, psoriasis, vitiligo, albinism, acne, alopecia and thousands of rare skin diseases.2 Dermatological diseases cause substantial pain, disfigurement, disability, and stigma while they also lead to serious comorbidities and significant psychological, social and financial burdens for patients and their families. \u00a0Theses diseases can be inflammatory, infectious and malignant, and are among the most prevalent and disabling disorders, particularly in low resource countries.<\/p>\n

Despite the substantial scale of this health burden, these diseases, unlike other noncommunicable diseases (NCDs) or neglected tropical diseases (NTDs), do not receive the global policy prioritisation they deserve. \u00a0Because skin diseases can occur at any age, they have a profoundly negative impact on the health and wellbeing of patients, their caregivers and families all around the world. Due to their frequent lifelong nature, dermatological conditions lead to sustained economic costs and can pose threats to healthcare systems.<\/p>\n

Formed in 2022, the Global Dermatology Coalition will advocate to the World Health Organization and other decision makers globally to elevate the healthcare prioritization of dermatological diseases. The multi-stakeholder group is focused on improving patient outcomes globally by raising awareness of the burdensome and multi-faceted impacts of these conditions.<\/p>\n

Collaborative action is needed to change the difficult reality faced by skin patients and for this reason we have established the Global Dermatology Coalition. Together, our organizations are actively working to improve patient outcomes globally. This would mean improved access to the diagnosis, care, treatments and support they need, when they need it \u2013 no matter where they live in the world.\u00a0 The Coalition speaks as one voice because people living with dermatological diseases, their caregivers and their families deserve to live without stigma, for their diseases not to be minimized and to achieve a higher quality of life.\u201d Marc Yale, Board President of the International Alliance of Dermatology Patient Organizations (also known as GlobalSkin) and Chair of the Global Dermatology Coalition Steering Committee.<\/p>\n

\u201cThe ILDS is committed to representing dermatology professionals, including representing over 191 member organisations from more than 90 countries, working with patient organisations to improve skin health for patients all around the world.\u00a0 As a founding partner of the Global Dermatology Coalition, we look forward to\u00a0utilising resources to foster collaboration, strengthen partnerships, develop networks to facilitate opportunities to raise awareness of the cross-cutting nature of skin health and impact global health policy. The ILDS is committed to the inclusion of the patient voice in our work; this coalition is part of a meaningful engagement in achieving that goal, and to improve the health and quality of life for patients.\u201d Luca Borradori, ILDS Board Member and healthcare professional representative for the Global Dermatology Coalition Steering Committee<\/p>\n

\u201cSkin as the largest organ and its diseases are little known and under-represented in the World Health Organization\u2019s non-communicable diseases agenda globally. The International Alliance of Patient Organizations (IAPO) is pleased to be a partner in the Global Dermatology Coalition which will urge the WHO and UN for change and recognition, so that all dermatological diseases are appropriately recognized for their significant burden on people around the world.<\/p>\n

The Global Dermatology Coalition consists of the following organisations:<\/p>\n

    \n
  1. CMTC-OVM.<\/li>\n
  2. Cutaneous Lymphoma Foundation.<\/li>\n
  3. Dermatology Nurses Association.<\/li>\n
  4. European Federation of Allergy and Airways Diseases Patients’ Associations (EFA).<\/li>\n
  5. European Society for Dermatological Research (ESDR).<\/li>\n
  6. Europso.<\/li>\n
  7. International Federation of Psoriatic Disease Associations (IFPA).<\/li>\n
  8. International League of Dermatological Societies (ILDS).<\/li>\n
  9. International Alliance of Dermatology Patient Organizations (GlobalSkin).<\/li>\n
  10. International Pemphigus Pemphigoid Foundation (IPPF).<\/li>\n
  11. La Roche-Posay International.<\/li>\n
  12. Lupus Europe.<\/li>\n
  13. Naevus Global.<\/li>\n
  14. Pediatric Dermatology Research Alliance (PeDRA).<\/li>\n
  15. Pfizer.<\/li>\n
  16. Regeneron.<\/li>\n
  17. Sanofi Genzyme.<\/li>\n<\/ol>\n

    Skin: largest organ of the body<\/p>\n